Price
No data yet.
Social Signal Score
Company Profile
- CEO
- Christoph Antz
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 8
- Beta
- 0.26
- Country
- DE
Quote
Valuation & Ratios
Returns & Efficiency
Valuation
VRXAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+140.00%Social Signal Score
Mentions (3)
- Newsbarrons.com·7h ago·Negative
Micro-Cap Stock Veraxa Biotech Is Down 96% This Year. Can Next-Gen Drug Testing Save It? Veraxa is shifting away from animal testing to get drugs to market faster, calling it ‘not just a regulatory obligation, but a scientific opportunity.'
View source ↗ - Newsglobenewswire.com·9h ago·Negative
VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy Consistent Use of New Approach Methodologies (NAMs) to Potentially Accelerate BiTAC® Oncology Pipeline and Significantly Reduce Animal Testing Needs.
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
VERAXA Biotech Appoints Raju Willener as Chief Financial Officer Zurich, Switzerland, Sept. 04, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the “Company”), a leading developer of next-generation antibody-based cancer therapies, today announced the appointment of Raju Willener as Chief Financial Officer (CFO), effective immediately.
View source ↗
Congress trades
No disclosed congressional trades in VRXA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.